University of Cincinnati

Total Page:16

File Type:pdf, Size:1020Kb

University of Cincinnati UNIVERSITY OF CINCINNATI Date: 28-May-2010 I, Emily Sites , hereby submit this original work as part of the requirements for the degree of: Master of Science in Genetic Counseling It is entitled: Copy Number Variation in Monozygotic Twins with NF1 Student Signature: Emily Sites This work and its defense approved by: Committee Chair: Lisa Martin, PhD Lisa Martin, PhD Teresa Smolarek, PhD Teresa Smolarek, PhD Elizabeth Schorry, MD Elizabeth Schorry, MD 5/27/2010 808 Copy Number Variation in Monozygotic Twins with NF1 Emily Sites M.S. University of Cincinnati December, 2008 University of Cincinnati Genetic Counseling Graduate Program College of Medicine Master’s Degree Thesis May 28th, 2010 Thesis Committee: Elizabeth Schorry, M.D. Teresa Smolarek, Ph.D. Lisa Martin, Ph.D. (Chair) Emily Sites Genetic Counseling Graduate Program Abstract for master’s thesis: Copy Number Variation in Monozygotic Twins with NF1 May 28th, 2010 General Abstract A major challenge of managing patients with Neurofibromatosis Type 1 (NF1) is the extreme variability of its phenotype, with no way to predict which patients are at high risk for serious complications. Family members and even monozygotic (MZ) twins with NF1 demonstrate inconsistent expression of the disease. The underlying mechanism for this discordance has never been elucidated. We propose that DNA copy number variants (CNVs), small deletions and duplications of genomic material, may contribute to the variability of disease manifestation. CNVs are known to differ between MZ twins and have recently been implicated in the etiology of several disorders including autism and schizophrenia Hypothesis: MZ twins with NF1 will have within-pair differences in CNVs that may explain their discordant NF1 complications, and CNVs will be present in larger numbers in NF1 patients compared to the general population. Methods: MZ twins with NF1, ages 5 to 18 years, were recruited from the CCHMC NF clinic population. Extensive data was collected for each twin’s NF1 features and complications. The Illumina 610k SNP microarray chip was used to identify and compare CNVs in peripheral blood from the twins and their parents. Age-matched controls were selected from a pre-existing CNV study population. Results: Of the five twin pairs reported here, three were discordant for optic pathway glioma, three for number of plexiform neurofibromas, one for pectus deformity, one for scoliosis, one for malignancy, and one pair was concordant for all parameters. We identified 43 CNVs meeting our conservative criteria, 18 of which overlap known or predicted genes. The average number of CNVs per twin pair was 8.6 with a range from 3 to 12. Of interest were five previously unreported areas of copy number change, two of which contain genes. We have yet to identify a de novo (non-familial) CNV. A larger study population would be needed to identify a correlation between familial CNVs and specific complications. Conclusions: Additional data is needed to determine if there is a correlative relationship between CNVs and NF1 phenotype. iii iv TABLE OF CONTENTS TITLE PAGE Introduction 1 Methods 6 Results 8 Discussion 12 Tables 18 Figures 22 References 24 v INTRODUCTION Neurofibromatosis Type 1 (NF1) is a tumor predisposition syndrome that affects one in thirty-five hundred live births. Individuals with NF1 are at an increased risk of developing both benign and malignant tumors. Other characteristics of the disease include café au lait spots, Lisch nodules of the iris, optic pathway gliomas, scoliosis, pectus deformities, other bone and vascular abnormalities and learning disabilities (Friedman and Birch 1997). Neurofibromatosis Type 1 was first described in 1882, and the gene responsible was cloned in 1990 (Ober 1978; Wallace, Marchuk et al. 1990). The 350kb NF1 gene is located at 17q11.2 (Daston, Scrable et al. 1992). One of the most challenging aspects of managing patients with NF1 is the extreme variability of phenotype. Currently, there is no way to predict which patients are at high risk for serious complications like malignancy, and to appropriately manage those at higher risk. Family members and even monozygotic (MZ) twins with NF1 demonstrate inconsistent expression of the disease. The underlying mechanism for this discordance has never been elucidated, although several have been proposed. These include: modifying genes, stochastic “2nd hit” events, environmental agents, epigenetic alterations, and post-zygotic (somatic) mutations. Despite extensive research, little evidence has been found to identify these factors or events. The search for other modifying genes has yielded little success to date. Second- hit, loss-of-heterozygosity events have been well-documented in several tumor types of NF1 and in at least one type of skeletal complication (Stevenson, Zhou et al. 2006), but are unlikely to explain the entire spectrum of NF1 features. Indeed, in NF1 1 neurofibromas, less than 50% of tumors have been found to have 2nd hit events in the NF1 gene, implying an additional mechanism at play (Wiest, Eisenbarth et al. 2003). Full gene deletions of NF1 can be associated with a more severe phenotype and higher tumor burden (Upadhyaya, Ruggieri et al. 1998), but no other significant genotype-phenotype correlations have been found. This full gene deletion, also referred to as NF1 microdeletion, occurs in only 5-10% of patients and predisposes individuals to more severe learning disabilities and facial dysmorphology, earlier or greater burden of cutaneous neurofibromas and possibly malignancy (Lopez Correa, Brems et al. 2000). It has been suggested that the severity of NF1 microdeletion is due to the concomitant loss of a group of genes adjacent to the NF1 gene, including CENTA2, RAB11FIP4, C17orf79, and UTP6 (Bartelt-Kirbach, Wuepping et al. 2009), but this has not been demonstrated conclusively. Twin studies have historically been a valuable tool for studying genetic disorders. Early genetic studies compared monozygotic twins raised separately to determine heritability of specific traits. The literature reports at least 24 pairs of proven MZ twins with NF1 [see References, Case Studies]. Easton et al. (Easton, Ponder et al. 1993) studied a large NF1 population, and found that NF1 features varied to a greater degree with increasing distance from a proband, with 6 pairs of MZ twins having the closest agreement in traits such as presence of neurofibromas, head circumference, and learning disabilities, compared to more distant relatives with NF1. They concluded that there was significant evidence for modifying loci affecting NF1 expression. Most other twin reports have been case reports. Some have shown remarkable concordance for NF1 features, although others have shown equally intriguing 2 discordancies. Most MZ twin pairs have been generally concordant for overall numbers of café-au-lait spots and cutaneous neurofibromas, implying control by genetic factors, although not solely by the NF1 gene. Presence and location of plexiform neurofibromas has generally been discordant in twin pairs, as expected if these tumors required a random, second-hit event. There have been surprising reports of concordance in other NF1 tumors such as optic nerve glioma (ONG; 6 pairs concordant, 5 pairs discordant) (Cartwright 1982; Crawford and Buckler 1983; Pascual-Castroviejo, Verdu et al. 1988; Kelly, Sproul et al. 1998), more than expected from the prevalence of ONG in 15% of children with NF1. Although MZ twins were historically assumed to be genetically identical, recent studies have shown remarkable differences in MZ twins in areas such as copy number variants (CNV)(Bruder, Piotrowski et al. 2008). Copy number variants are microduplications or deletions of DNA that are typically defined as being larger than 1 kilobase (kb), and now known to be widespread throughout the human genome (Scherer, Lee et al. 2007). There is mounting evidence that CNVs have played a significant role in normal population variation, evolution, and disease predisposition (Wong, deLeeuw et al. 2007; McCarroll, Kuruvilla et al. 2008). Genes involved in immunity and defense, sensory perception, and cell adhesion have been found to be associated with CNVs (Conrad, Andrews et al. 2006). Significant CNV associations have been found in schizophrenia and autism (Sebat, Lakshmi et al. 2007; Xu, Roos et al. 2008). Some CNVs represent recurrent polymorphisms occurring at a low rate in the population and have no known clinical significance. However, more than 50% of CNVs occur in areas of known genes and could potentially cause significant phenotypic effect 3 (Iafrate, Feuk et al. 2004). The average individual in the general population will be found to have at least 10-50 CNVs using current SNP-based microarrays, with the majority of those (>90%) being familial (Iafrate, Feuk et al. 2004; Conrad, Andrews et al. 2006; McCarroll, Kuruvilla et al. 2008). The incidence of CNVs depends greatly on methodology used, and it is likely that the numbers demonstrated to date represent only the tip of the iceberg. De novo CNVs are those found in a proband, but neither parent, and in our case perhaps only one twin. These are thought to arise either in a germ cell or in the early embryo. If a CNV were present in only one of a pair of MZ twins, we would expect that the change occurred sometime after division of the 2 embryos. De novo CNVs which occur during post-fertilization may have a mosaic distribution thoughout the body. This could potentially be detected by sampling tissues representative of multiple germ layers. We sampled both blood (mesoderm) and buccal (ectoderm) cells to investigate this possibility. De novo CNVs are generally thought to be a likely cause of phenotypic abnormality. Bruder et al. studied whole-genome CNV in MZ twin pairs discordant for Parkinsonian disease and compared them to CNVs in unselected and concordant MZ twin pairs. They found multiple CNVs in all twin pairs, most in mosaic form, and concluded that these differences represented an example of somatic mosaicism. This group utilized both the Illumina 300k SNP array and 32K BAC array platforms and were reportedly able to detect CNVs with as low as 10% mosaicism.
Recommended publications
  • Supplementary Data
    Figure 2S 4 7 A - C 080125 CSCs 080418 CSCs - + IFN-a 48 h + IFN-a 48 h + IFN-a 72 h 6 + IFN-a 72 h 3 5 MRFI 4 2 3 2 1 1 0 0 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 7 B 13 080125 FBS - D 080418 FBS - + IFN-a 48 h 12 + IFN-a 48 h + IFN-a 72 h + IFN-a 72 h 6 080125 FBS 11 10 5 9 8 4 7 6 3 MRFI 5 4 2 3 2 1 1 0 0 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 MHC I MHC II MICA MICB ULBP-1 ULBP-2 ULBP-3 ULBP-4 Molecule Molecule FIGURE 4S FIGURE 5S Panel A Panel B FIGURE 6S A B C D Supplemental Results Table 1S. Modulation by IFN-α of APM in GBM CSC and FBS tumor cell lines. Molecule * Cell line IFN-α‡ HLA β2-m# HLA LMP TAP1 TAP2 class II A A HC§ 2 7 10 080125 CSCs - 1∞ (1) 3 (65) 2 (91) 1 (2) 6 (47) 2 (61) 1 (3) 1 (2) 1 (3) + 2 (81) 11 (80) 13 (99) 1 (3) 8 (88) 4 (91) 1 (2) 1 (3) 2 (68) 080125 FBS - 2 (81) 4 (63) 4 (83) 1 (3) 6 (80) 3 (67) 2 (86) 1 (3) 2 (75) + 2 (99) 14 (90) 7 (97) 5 (75) 7 (100) 6 (98) 2 (90) 1 (4) 3 (87) 080418 CSCs - 2 (51) 1 (1) 1 (3) 2 (47) 2 (83) 2 (54) 1 (4) 1 (2) 1 (3) + 2 (81) 3 (76) 5 (75) 2 (50) 2 (83) 3 (71) 1 (3) 2 (87) 1 (2) 080418 FBS - 1 (3) 3 (70) 2 (88) 1 (4) 3 (87) 2 (76) 1 (3) 1 (3) 1 (2) + 2 (78) 7 (98) 5 (99) 2 (94) 5 (100) 3 (100) 1 (4) 2 (100) 1 (2) 070104 CSCs - 1 (2) 1 (3) 1 (3) 2 (78) 1 (3) 1 (2) 1 (3) 1 (3) 1 (2) + 2 (98) 8 (100) 10 (88) 4 (89) 3 (98) 3 (94) 1 (4) 2 (86) 2 (79) * expression of APM molecules was evaluated by intracellular staining and cytofluorimetric analysis; ‡ cells were treatead or not (+/-) for 72 h with 1000 IU/ml of IFN-α; # β-2 microglobulin; § β-2 microglobulin-free HLA-A heavy chain; ∞ values are indicated as ratio between the mean of fluorescence intensity of cells stained with the selected mAb and that of the negative control; bold values indicate significant MRFI (≥ 2).
    [Show full text]
  • Analysis of Gene Expression Data for Gene Ontology
    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
    [Show full text]
  • Tepzz¥ 6Z54za T
    (19) TZZ¥ ZZ_T (11) EP 3 260 540 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.12.2017 Bulletin 2017/52 C12N 15/113 (2010.01) A61K 9/127 (2006.01) A61K 31/713 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 17000579.7 (22) Date of filing: 12.11.2011 (84) Designated Contracting States: • Sarma, Kavitha AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Philadelphia, PA 19146 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Borowsky, Mark PL PT RO RS SE SI SK SM TR Needham, MA 02494 (US) • Ohsumi, Toshiro Kendrick (30) Priority: 12.11.2010 US 412862 P Cambridge, MA 02141 (US) 20.12.2010 US 201061425174 P 28.07.2011 US 201161512754 P (74) Representative: Clegg, Richard Ian et al Mewburn Ellis LLP (62) Document number(s) of the earlier application(s) in City Tower accordance with Art. 76 EPC: 40 Basinghall Street 11840099.3 / 2 638 163 London EC2V 5DE (GB) (71) Applicant: The General Hospital Corporation Remarks: Boston, MA 02114 (US) •Thecomplete document including Reference Tables and the Sequence Listing can be downloaded from (72) Inventors: the EPO website • Lee, Jeannie T •This application was filed on 05-04-2017 as a Boston, MA 02114 (US) divisional application to the application mentioned • Zhao, Jing under INID code 62. San Diego, CA 92122 (US) •Claims filed after the date of receipt of the divisional application (Rule 68(4) EPC). (54) POLYCOMB-ASSOCIATED NON-CODING RNAS (57) This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs.
    [Show full text]
  • Essential Genes and Their Role in Autism Spectrum Disorder
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Essential Genes And Their Role In Autism Spectrum Disorder Xiao Ji University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, and the Genetics Commons Recommended Citation Ji, Xiao, "Essential Genes And Their Role In Autism Spectrum Disorder" (2017). Publicly Accessible Penn Dissertations. 2369. https://repository.upenn.edu/edissertations/2369 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2369 For more information, please contact [email protected]. Essential Genes And Their Role In Autism Spectrum Disorder Abstract Essential genes (EGs) play central roles in fundamental cellular processes and are required for the survival of an organism. EGs are enriched for human disease genes and are under strong purifying selection. This intolerance to deleterious mutations, commonly observed haploinsufficiency and the importance of EGs in pre- and postnatal development suggests a possible cumulative effect of deleterious variants in EGs on complex neurodevelopmental disorders. Autism spectrum disorder (ASD) is a heterogeneous, highly heritable neurodevelopmental syndrome characterized by impaired social interaction, communication and repetitive behavior. More and more genetic evidence points to a polygenic model of ASD and it is estimated that hundreds of genes contribute to ASD. The central question addressed in this dissertation is whether genes with a strong effect on survival and fitness (i.e. EGs) play a specific oler in ASD risk. I compiled a comprehensive catalog of 3,915 mammalian EGs by combining human orthologs of lethal genes in knockout mice and genes responsible for cell-based essentiality.
    [Show full text]
  • Characterization of a 7.6-Mb Germline Deletion Encompassing the NF1 Locus and About a Hundred Genes in an NF1 Contiguous Gene Syndrome Patient
    European Journal of Human Genetics (2008) 16, 1459–1466 & 2008 Macmillan Publishers Limited All rights reserved 1018-4813/08 $32.00 www.nature.com/ejhg ARTICLE Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient Eric Pasmant*,1,2, Aure´lie de Saint-Trivier2, Ingrid Laurendeau1, Anne Dieux-Coeslier3, Be´atrice Parfait1,2, Michel Vidaud1,2, Dominique Vidaud1,2 and Ivan Bie`che1,2 1UMR745 INSERM, Universite´ Paris Descartes, Faculte´ des Sciences Pharmaceutiques et Biologiques, Paris, France; 2Service de Biochimie et de Ge´ne´tique Mole´culaire, Hoˆpital Beaujon AP-HP, Clichy, France; 3Service de Ge´ne´tique Clinique, Hoˆpital Jeanne de Flandre, Lille, France We describe a large germline deletion removing the NF1 locus, identified by heterozygosity mapping based on microsatellite markers, in an 8-year-old French girl with a particularly severe NF1 contiguous gene syndrome. We used gene-dose mapping with sequence-tagged site real-time PCR to locate the deletion end points, which were precisely characterized by means of long-range PCR and nucleotide sequencing. The deletion is located on chromosome arm 17q and is exactly 7 586 986 bp long. It encompasses the entire NF1 locus and about 100 other genes, including numerous chemokine genes, an attractive in silico-selected cerebrally expressed candidate gene (designated NUFIP2, for nuclear fragile X mental retardation protein interacting protein 2; NM_020772) and four microRNA genes. Interestingly, the centromeric breakpoint is located in intron 4 of the PIPOX gene (pipecolic acid oxidase; NM_016518) and the telomeric breakpoint in intron 5 of the GGNBP2 gene (gametogenetin binding protein 2; NM_024835) coding a transcription factor.
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma
    Research Article Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma Chunhua Lu,1 Tomas Bonome,3 Yang Li,1 Aparna A. Kamat,1 Liz Y. Han,1 Rosemarie Schmandt,1 Robert L. Coleman,1 David M. Gershenson,1 Robert B. Jaffe,4 MichaelJ. Birrer, 3 and AnilK. Sood 1,2 Departments of 1Gynecologic Oncology and 2Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas; 3Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland; and 4Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California Abstract the promise of such approaches. However, the full spectrum of Therapeutic strategies based on antiangiogenic approaches differences in the tumor vasculature compared with its normal are beginning to show great promise in clinical studies. counterpart is not known. Identification of additional targets on However, full realization of these approaches requires tumor endothelium may allow opportunities for developing new identification of key differences in gene expression between therapeutic approaches to inhibit angiogenesis in a tumor-specific endothelial cells from tumors versus their normal counter- manner. parts. Here, we examined gene expression differences in Higher levels of proangiogenic cytokines and angiogenesis are purified endothelial cells from 10invasive epithelial ovarian associated with an increased risk of metastasis and poor prognosis cancers and 5 normal ovaries using Affymetrix U133 Plus in ovarian cancer (5, 6). To date, a small number of breast, colon, 2.0microarrays. More than 400differentially expressed genes and brain cancers have been analyzed for gene expression changes were identified in tumor-associated endothelial cells.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Bioinformatic Analysis of Autism Positional Candidate Genes Using Biological Databases and Computational Gene Network Prediction
    Genes, Brain and Behavior (2003) 2: 303–320 Copyright # Blackwell Munksgaard 2003 Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction A. L. Yonan†,‡, A. A. Palmer†, K. C. Smith†, inform studies of autism, and to illustrate and explore I. Feldman†,††, H. K. Lee†, J. M. Yonan§, the increasing potential of bioinformatic approaches as † †,†† *,†,‡, S. G. Fischer , P. Pavlidis and T. C. Gilliam { a compliment to linkage analysis. Keywords: 17q, AGRE sample, autism, association studies, †Columbia Genome Center, Columbia University, New York, bioinformatics, candidate genes ‡ Department of Genetics and Development, Columbia University, Received 30 June 2003, revised 20 August 2003, accepted New York, for publication 21 August 2003 ¶Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, §Division of Molecular Genetics, Departments of Pediatrics and Medicine, Columbia University, New York, Autism is a pervasive neurodevelopmental disorder that ††Department of Biomedical Informatics, Columbia University, severely impairs development of normal social and emotional New York, USA interactions and related forms of communication. Disease *Corresponding author: T. C. Gilliam, Columbia Genome Center, symptoms characteristically include unusually restricted and 1150 St. Nicholas Avenue, Room 508, New York, NY 10032, USA. E-mail: [email protected] stereotyped patterns of behaviors and interests. Autism describes the most severe manifestation
    [Show full text]
  • Utpa and Utpb Chaperone Nascent Pre-Ribosomal RNA and U3 Snorna to Initiate Eukaryotic Ribosome Assembly
    ARTICLE Received 6 Apr 2016 | Accepted 27 May 2016 | Published 29 Jun 2016 DOI: 10.1038/ncomms12090 OPEN UtpA and UtpB chaperone nascent pre-ribosomal RNA and U3 snoRNA to initiate eukaryotic ribosome assembly Mirjam Hunziker1,*, Jonas Barandun1,*, Elisabeth Petfalski2, Dongyan Tan3, Cle´mentine Delan-Forino2, Kelly R. Molloy4, Kelly H. Kim5, Hywel Dunn-Davies2, Yi Shi4, Malik Chaker-Margot1,6, Brian T. Chait4, Thomas Walz5, David Tollervey2 & Sebastian Klinge1 Early eukaryotic ribosome biogenesis involves large multi-protein complexes, which co-transcriptionally associate with pre-ribosomal RNA to form the small subunit processome. The precise mechanisms by which two of the largest multi-protein complexes—UtpA and UtpB—interact with nascent pre-ribosomal RNA are poorly understood. Here, we combined biochemical and structural biology approaches with ensembles of RNA–protein cross-linking data to elucidate the essential functions of both complexes. We show that UtpA contains a large composite RNA-binding site and captures the 50 end of pre-ribosomal RNA. UtpB forms an extended structure that binds early pre-ribosomal intermediates in close proximity to architectural sites such as an RNA duplex formed by the 50 ETS and U3 snoRNA as well as the 30 boundary of the 18S rRNA. Both complexes therefore act as vital RNA chaperones to initiate eukaryotic ribosome assembly. 1 Laboratory of Protein and Nucleic Acid Chemistry, The Rockefeller University, New York, New York 10065, USA. 2 Wellcome Trust Centre for Cell Biology, University of Edinburgh, Michael Swann Building, Max Born Crescent, Edinburgh EH9 3BF, UK. 3 Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
    [Show full text]
  • Molecular Classification of Diffuse Cerebral WHO Grade II/III Gliomas
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups Weller, Michael ; Weber, Ruthild G ; Willscher, Edith ; Riehmer, Vera ; Hentschel, Bettina ; Kreuz, Markus ; Felsberg, Jörg ; Beyer, Ulrike ; Löffler-Wirth, Henry ; Kaulich, Kerstin ; Steinbach, Joachim P ; Hartmann, Christian ; Gramatzki, D ; Schramm, J ; Westphal, M ; Schackert, G ; Simon, M ; Martens, T ; Boström, J ; Hagel, C ; Sabel, M ; Krex, D ; Tonn, J C ; Wick, W ; Noell, S ; Schlegel, U ; Radlwimmer, B ; Pietsch, T ; Loeffler, M ; von Deimling, A ; Binder, H ; Reifenberger, G Abstract: Cerebral gliomas of World Health Organization (WHO) grade II and III represent a major challenge in terms of histological classification and clinical management. Here, we asked whether large- scale genomic and transcriptomic profiling improves the definition of prognostically distinct entities. We performed microarray-based genome- and transcriptome-wide analyses of primary tumor samples from a prospective German Glioma Network cohort of 137 patients with cerebral gliomas, including 61 WHO grade II and 76 WHO grade III tumors. Integrative bioinformatic analyses were employed to define molecular subgroups, which were then related to histology, molecular biomarkers, including isocitrate de- hydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q co-deletion and telomerase reverse transcriptase (TERT) promoter mutations, and patient outcome. Genomic profiling identified five distinct glioma groups, in- cluding three IDH1/2 mutant and two IDH1/2 wild-type groups. Expression profiling revealed evidence for eight transcriptionally different groups (five IDH1/2 mutant, three IDH1/2 wild type), which were only partially linked to the genomic groups.
    [Show full text]
  • The Complete Structure of the Small-Subunit Processome
    ARTICLES The complete structure of the small-subunit processome Jonas Barandun1,4 , Malik Chaker-Margot1,2,4 , Mirjam Hunziker1,4 , Kelly R Molloy3, Brian T Chait3 & Sebastian Klinge1 The small-subunit processome represents the earliest stable precursor of the eukaryotic small ribosomal subunit. Here we present the cryo-EM structure of the Saccharomyces cerevisiae small-subunit processome at an overall resolution of 3.8 Å, which provides an essentially complete near-atomic model of this assembly. In this nucleolar superstructure, 51 ribosome-assembly factors and two RNAs encapsulate the 18S rRNA precursor and 15 ribosomal proteins in a state that precedes pre-rRNA cleavage at site A1. Extended flexible proteins are employed to connect distant sites in this particle. Molecular mimicry and steric hindrance, as well as protein- and RNA-mediated RNA remodeling, are used in a concerted fashion to prevent the premature formation of the central pseudoknot and its surrounding elements within the small ribosomal subunit. Eukaryotic ribosome assembly is a highly dynamic process involving during which the four rRNA domains of the 18S rRNA (5′, central, in excess of 200 non-ribosomal proteins and RNAs. This process 3′ major and 3′ minor) are bound by a set of specific ribosome-assem- starts in the nucleolus where rRNAs for the small ribosomal subunit bly factors7,8. Biochemical studies indicated that these factors and the (18S rRNA) and the large ribosomal subunit (25S and 5.8S rRNA) 5′-ETS particle probably contribute to the independent maturation are initially transcribed as part of a large 35S pre-rRNA precursor of the domains of the SSU7,8.
    [Show full text]